Table 2 Correlation between c-maf expression and treatment response of multiple myeloma patients
From: Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
|  | All patients (n = 116) | C-maf-positive (n = 36) | C-maf-negative (n = 80) | p value |
|---|---|---|---|---|
Therapy, n (%) | ||||
 Bor | 70 (60.3) | 22 (61.1) | 48 (60.0) |  |
 Non-bor | 46 (39.7) | 14 (38.9) | 32 (40.0) | 0.910 |
Courses, n (%) | ||||
 <3 | 44 (37.9) | 11 (30.6) | 33 (41.3) |  |
 ≥3 | 72 (62.1) | 25 (69.4) | 47 (58.7) | 0.272 |
Response (ORR), n (%) | ||||
 <PR | 50 (46.9) | 12 (43.6) | 38 (48.3) |  |
 ≥PR | 66 (53.1) | 24 (56.4) | 42 (51.7) | 0.154 |
Response (VGPR), n (%) | ||||
 <VGPR | 63 (54.3) | 22 (61.1) | 41 (51.3) |  |
 ≥VGPR | 53 (45.7) | 14 (38.9) | 39 (48.7) | 0.324 |
Courses ≥3 | N = 69 | N = 24 | N = 45 |  |
|---|---|---|---|---|
Response (ORR), n (%) | ||||
 <PR | 7 (10.1) | 3 (12.5) | 4 (8.9) |  |
 ≥PR | 62 (89.9) | 21 (87.5) | 41 (91.1) | 0.641 |
Response (VGPR), n (%) | ||||
 <VGPR | 20 (29.0) | 10 (41.7) | 10 (22.2) |  |
 ≥VGPR | 49 (71.0) | 14 (58.3) | 35 (77.8) | 0.090 |
Bortezomib | NÂ =Â 48 | NÂ =Â 16 | NÂ =Â 32 | Â |
|---|---|---|---|---|
Response (ORR), n (%) | ||||
 <PR | 4 (8.3) | 1 (6.3) | 3 (9.4) |  |
 ≥PR | 44 (91.7) | 15 (93.7) | 29 (90.6) | 0.712 |
Response (VGPR), n (%) | ||||
 <VGPR | 10 (20.8) | 3 (18.8) | 7 (21.9) |  |
 ≥VGPR | 38 (79.2) | 13 (81.2) | 25 (78.1) | 0.800 |
Non-bortezomib | NÂ =Â 21 | NÂ =Â 8 | NÂ =Â 13 | Â |
|---|---|---|---|---|
Response (ORR), n (%) | ||||
 <PR | 3 (14.3) | 2 (25.0) | 1 (7.7) |  |
 ≥PR | 18 (85.7) | 6 (75.0) | 12 (92.3) | 0.278 |
Response (ORR), n (%) | ||||
 <VGPR | 10 (47.6) | 7 (87.5) | 3 (23.1) |  |
 ≥VGPR | 11 (52.4) | 1 (12.5) | 10 (76.9) | 0.003 |